Selexis, Pieris in Licensing Pact

Selexis, a Geneva, Switzerland-based life sciences company, has signed a license agreement that provides Pieris Pharmaceuticals, based in Boston, Massachusetts, access to Selexis’ SUREtechnology platform and SURE CHO-M cell line to advance development of Pieris’ lead bispecific immuno-oncology drug candidate, PRS-343.

Selexis’ SUREtechnology platform facilitates production of recombinant proteins.The Selexis SURE CHO-M cell line is a mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. Therapeutics that are generated using Selexis SURE CHO-M cells are used in clinical-trial material supply and marketed products.

Source: Selexis

Leave a Reply

Your email address will not be published. Required fields are marked *